Your browser doesn't support javascript.
loading
Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex.
Houston, John P; Ahl, Jonna; Meyers, Adam L; Kaiser, Christopher J; Tohen, Mauricio; Baldessarini, Ross J.
Afiliación
  • Houston JP; Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, IN 46221, USA. houstonjp@lilly.com
J Clin Psychiatry ; 67(8): 1246-52, 2006 Aug.
Article en En | MEDLINE | ID: mdl-16965203
ABSTRACT

OBJECTIVE:

To identify symptoms associated with suicidality in bipolar I disorder patients, and to assess suicide risk during treatment with olan-zapine in combination with lithium or divalproex.

METHOD:

We used data from a study (conducted from September 1997 to October 2000) in which DSM-IV bipolar I manic or mixed-episode patients who were partially responsive to at least 2 weeks of lithium or dival-proex monotherapy prior to study entry were randomly assigned to augmentation therapy with olanzapine (5-20 mg/day) or placebo. Among mixed-episode patients with residual suicidality (Hamilton Rating Scale for Depression-item 3 [HAM-D-3] score of 1 or above) at randomization to cotherapy, we identified items in the Young Mania Rating Scale, Positive and Negative Syndrome Scale, and Barnes Akathisia Rating Scale that correlated with HAM-D-3 scores. We used factor analysis of correlated items to identify symptom domains associated with suicidality ratings and assessed changes in symptom factors and HAM-D-3 scores during 6 weeks of combination therapy with olanzapine versus placebo.

RESULTS:

In 58 mixed-episode patients, mean +/- SD HAM-D-3 scores averaged 1.36 +/- 0.55 after at least 2 weeks of initial mood stabilizer monotherapy prior to study entry. Factors associated with the HAM-D-3 appeared to represent somatic discomfort, agitated depression, and psychotic features. Combination therapy with olanzapine (N = 36) versus placebo (N = 22) differentially reduced HAM-D-3 scores by 58% versus 29% (p < .05) within 1 week, and all 3 associated symptom factors within 2 weeks by averages of 31% versus 12% (p < .05).

CONCLUSIONS:

Suicidality in adult, mixed-episode, bipolar I disorder patients was associated with somatic discomfort, agitated depression, and psychosis. Overall, these findings suggest that the addition of an atypical antipsychotic-antimanic agent in some bipolar disorder patients may help to reduce suicidal ideation.
Asunto(s)
Buscar en Google
Bases de datos: MEDLINE Asunto principal: Suicidio / Antipsicóticos / Trastorno Bipolar / Ácido Valproico / Litio / Anticonvulsivantes Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Psychiatry Año: 2006 Tipo del documento: Article País de afiliación: Estados Unidos
Buscar en Google
Bases de datos: MEDLINE Asunto principal: Suicidio / Antipsicóticos / Trastorno Bipolar / Ácido Valproico / Litio / Anticonvulsivantes Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Psychiatry Año: 2006 Tipo del documento: Article País de afiliación: Estados Unidos